ArticleFrontiers in medicine2018
Vaccine Immunotherapy for Celiac Disease.
Article in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Review
- Gluten intake and its possible relationship with pain, skin symptoms, and mental health in the Spanish population: an observational study.Frontiers in nutrition · 2026Article
- The follow-up of patients with celiac disease.Journal of translational autoimmunity · 2025Review
- Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies.Nutrients · 2024Review
- Potential determinants of vaccine hesitancy among celiac disease patients: a single cohort analysis.Frontiers in public health · 2023Article
- Replacing the Burden of the Gluten Free Diet: Then, Now, and the Future.International journal of molecular sciences · 2022Review
- A Comprehensive Review of the Neurological Manifestations of Celiac Disease and Its Treatment.Diseases (Basel, Switzerland) · 2022Review
- Review
- Celiac Disease Causes Epithelial Disruption and Regulatory T Cell Recruitment in the Oral Mucosa.Frontiers in immunology · 2021Article
- Novel Therapeutic Strategies for Celiac Disease.Middle East journal of digestive diseases · 2020Review
- Vaccination against autoimmune diseases moves closer to the clinic.Human vaccines & immunotherapeutics · 2020Review
- Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease.Cells · 2019Review
- Article
- The gliadin-CFTR connection: new perspectives for the treatment of celiac disease.Italian journal of pediatrics · 2019Article
- Defective proteostasis in celiac disease as a new therapeutic target.Cell death & disease · 2019Review
- Novel targets for drug discovery in celiac disease.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune and allergic disorders are highly prevalent conditions in which an altered or abnormal immune response is mounted against self- or environmental antigens, respectively. Antigen-based immunotherapy is a therapeutic option aimed at restoring the specific immune tolerance toward pathogenic antigens while leaving the rest of the immune system unaffected. This strategy proved efficacy especially in allergic diseases, including asthma, allergic rhinitis, and food allergies, but still has shortcomings for the treatment of autoimmune diseases. However, there are no available therapies, currently, in clinical practice for restoring the physiological tolerance that is typically lost in autoimmune diseases. In celiac disease, which is a common immune-mediated enteropathy triggered by the ingestion of gluten in genetically susceptible individuals, antigen-based immunotherapy could be a feasible option thanks to our deep understanding of the pathogenic mechanisms underpinning this condition. In fact, the immunodominant gluten epitopes are well-characterized and are recognized by pathogenic CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.